Testing for the integrity of blinding in clinical trials: How valid are forced choice paradigms?

Psychotherapy and Psychosomatics

Volumn 72, Issue 3, 2003, Pages 128-131

  Sharpe, Louise ^a   Ryan, Bridget ^b   Allard, Simon ^b   Sensky, Tom ^c  

^a UNIVERSITY OF SYDNEY   (Australia)

^b WEST MIDDLESEX UNIVERSITY HOSPITAL   (United Kingdom)

^c IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

Allocation concealment; Bias; Blinding; Clinical trial design; Methodology; Randomized controlled trials

Indexed keywords

ACCURACY; ARTICLE; BEHAVIOR THERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; COGNITIVE THERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; HEALTH CARE; HUMAN; METHODOLOGY; PREDICTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RHEUMATOID ARTHRITIS; SINGLE BLIND PROCEDURE;

ARTHRITIS, RHEUMATOID; COGNITIVE THERAPY; DOUBLE-BLIND METHOD; HUMANS; RANDOMIZED CONTROLLED TRIALS; REPRODUCIBILITY OF RESULTS; RESEARCH DESIGN;

EID: 0037262788     PISSN: 00333190     EISSN: None     Source Type: Journal    
DOI: 10.1159/000069736     Document Type: Article

References (13)

1. Brownell KD, Stunkard AJ: The double-blind in danger: Untoward consequences of informed consent. Am J Psychiatry 1982;139:1487-1489.
2. Engelhardt DM, Margolis RA, Rudorfer L, Paley HM: Physician bias and the double-blind. Arch Gen Psychiatry 1969;20:315-320.
3. Rabkin JG, Markowitz JS, Stewart J, McGrath P, Harrison W, Quitkin FM, Klein DF: How blind is blind? Assessment of patient and doctor medication guesses in a placebo-controlled trial of imipramine and phenelzine. Psychiatr Res 1986;19:75-86.
4. Fisher S, Greenberg RP: How blind is the double-blind design for evaluating psychotropic drugs? J Nerv Ment Dis 1993;181:345-350.
5. Basoglu M, Marks I, Livanou M, Swinson R: Double-blindness procedures, rater blindness and ratings of outcome: Observations from a controlled trial. Arch Gen Psychiatry 1997;54:744-748.
6. Antonuccio DO, Danton WG, De Nelsky GY, Greenberg RP, Gordon JS: Raising questions about antidepressants. Psychother Psychosom 1999;68:3-14.
7. Even C, Siobud-Dorocant E, Dardennes RM: Critical approach to anti-depressant trials: Blindness protection is necessary, feasible and measurable. Br J Psychiatry 2000;177:47-51.
8. Sharpe L, Sensky T, Timberlake N, Ryan B, Brewin CR, Allard S: A blind, randomised controlled trial of cognitive-behavioural intervention for patients with recent onset rheumatoid arthritis: Preventing psychological and physical morbidity. Pain 2001;89:275-283.
9. Sharpe L, Sensky T, Timberlake N, Ryan B, Allard S: Long-term efficacy of a cognitive behavioural treatment for patients recently diagnosed with rheumatoid arthritis. Rheumatology, in press.
10. Devlin J, Gough A, Huissoon A, Perkins P, Holder R, Reece R, Arthur V, Emery P: The acute phase function in early rheumatoid arthritis: C-reactive protein levels correlate with functional outcome. J Rheumatol 1997;24:9-13.
11. Wolfe F: Comparative usefulness of C-reactive protein and erythrocyte sedimentation rate in patients with rheumatoid arthritis. J Rheumatol 1997;24:1477-1485.
12. Bakker A, Spinhoven P, van der Does AJ, van Balkom AJ, van Dyck R: Locus of control orientation in panic disorder and the differential effects of treatment. Psychother Psychosom 2002;71:85-89.
13. Bakker A, Spinhoven P, van Balkom AJLM, van Dyck R: Relevance of assessment of cognitions during panic attacks in the treatment of panic disorder. Psychother Psychosom 2002;71:158-161.